BradleyLawrenceFreilichMDFAASLD,AGAF, CCI

Advanced Endoscopic Interventional, Hepatology & Liver Transplantation, Inflammatory Bowel Disease, Bariatric Medicine

Partner Kansas City Gastroenterology Director Liver and Pancreas Institute of Kansas City Director Kansas City Research Institute Director HCA Metabolic Syndrome/Weight Loss Center

Join to view full profile

Dr. Freilich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Freilich's full profile

Already have an account?

Office
6675 Holmes Rd Ste 430
Kansas City, MO 64131
Phone+1 816-361-0055

Fax+1 816-361-5775
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1991 - 1994
Rush University Medical CenterResidency, Internal Medicine, 1988 - 1991
University of Missouri Kansas City School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 1991 - Present
KS State Medical License 1994 - 2024
MO State Medical License 1994 - 2024
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Fellow (AGAF) American Gastroenterological Association, 2006

Clinical Trials

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Start of enrollment: 2014 Mar 27
Completed
Phase 3
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Start of enrollment: 2014 Apr 01
Completed
Phase 3
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Stephen A Harrison, Peter J Ruane, Bradley Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Reshma Shringarpure, Brittany de Temple, Erica Fong, Erik J Til...> ;JHEP Reports. 2023 Jan 1
15 citations
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy, Naim Alkhouri, Mustafa R Bashir, Bradley Freilich, Anita Kohli, Arun Khazanchi, Muhammad ...> ;The Lancet. Gastroenterology & Hepatology. 2022 Jul 1
7 citations
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.
Yasser Fouad, Melissa Palmer, Minjun Chen, Arie Regev, Rajarshi Banerjee, Rob Myers, Robert Riccio, Richard Torstenson, Ramy Younes, Puneet S Arora, Henrik Landgren, M...> ;Journal of Clinical and Translational Hepatology. 2022 Apr 28
36 citations
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
Philip N. Newsome, Melissa Palmer, Bradley Freilich, Muhammad Y. Sheikh, Aasim Sheikh, Harry Sarles, Robert Herring, Parvez S. Mantry, Zeid Kayali, Tarek Hassanein, Ha...> ;Journal of Hepatology. 2020 Aug 1
125 citations
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Stephen A. Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad Younes, Bradley Freilich, Muhammad Y. Sheikh, Jörn M. Schattenberg, Zeid Kayali, Adam Zivony...> ;Journal of Hepatology. 2020 May 1
62 citations
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Mitchell L. Shiffman, Bradley Freilich, Raj Vuppalanchi, Kymberly D. Watt, Jean L. Chan, Al Spada, David T. Hagerty, Eugene R. Schiff> ;Alimentary Pharmacology & Therapeutics. 2019 Jan 1
92 citations
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, ra...
David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael R Galambos, Bruce R Bacon, Yvonne Doerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, Dav...> ;The Lancet. Gastroenterology & Hepatology. 2017 Oct 1
38 citations
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
Maribel Rodriguez-Torres, S. Glass, Jae H. Hill, B. Freilich, D. Hassman, A. M. Di Bisceglie, Joseph Taylor, Brian J. Kirby, Hadas Dvory-Sobol, Julia C. Yang, Di An, L...> ;Journal of Viral Hepatitis. 2016 Aug 1
35 citations
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Eric Lawitz, William D. O'Riordan, Armen Asatryan, Bradley L. Freilich, Terry Box, J Scott Overcash, Sandra S. Lovell, Teresa I. Ng, W. Liu, Campbell Andrew L, C.-W. L...> ;Antimicrobial Agents and Chemotherapy. 2016 Mar 1
41 citations
A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus
Eric Lawitz, B. Freilich, John O. Link, P. German, Hongmei Mo, L. Han, Diana M. Brainard, John McNally, Thomas Marbury, Maribel Rodriguez-Torres> ;Journal of Viral Hepatitis. 2015 Dec 1
144 citations
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
E.J. Gane, Young-Suk Lim, Stuart C. Gordon, Kumar Visvanathan, Eric Sicard, Richard N. Fedorak, Stuart K. Roberts, Benedetta Massetto, Zhishen Ye, Stefan Pflanz, Kimbe...> ;Journal of Hepatology. 2015 Aug 1
50 citations
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Tariq Ahmad, Philip D. Yin, Jeffrey E. Saffitz, Paul J. Pockros, Jacob Lalezari, Mitchell L. Shiffman, B. Freilich, Joann Zamparo, Kyle Brown, Dessislava Dimitrova, Mo...> ;Hepatology. 2015 Aug 1
240 citations
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a rand...
Eric Lawitz, J. Lalezari, Tarek Hassanein, Kris V. Kowdley, Fred Poordad, Aasim Sheikh, Nezam H. Afdhal, David E. Bernstein, E. DeJesus, B. Freilich, David R. Nelson, ...> ;The Lancet. Infectious Diseases. 2013 May 1
15 citations
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial.
Ke-Qin Hu, B. Freilich, Robert S. Brown, Clifford A. Brass, Ira M. Jacobson> ;Journal of Clinical Gastroenterology. 2011 Sep 1
558 citations
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson, Andrew J. Muir, Mark S. Sulkowski, Dongliang Ge, Jacques Fellay, Kevin V. Shianna, Thomas J. Urban, Nezam H. Afdhal, Ira M. Jacobson, Rafael Est...> ;Gastroenterology. 2010 Jul 1
53 citations
Impact of weight‐based ribavirin with peginterferon alfa‐2b in african americans with hepatitis C virus genotype 1
Ira M. Jacobson, Robert S. Brown, Jonathan McCone, Martin Black, Clive Albert, Michael S. Dragutsky, Firdous Siddiqui, Thomas Hargrave, Paul Y. Kwo, Louis R. Lambiase,...> ;Hepatology. 2007 Oct 1
211 citations
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial
Ira M. Jacobson, Robert S. Brown, B. Freilich, Nezam H. Afdhal, P. Kwo, John J. Santoro, Scott Becker, Adil E. Wakil, David Pound, Eliot Godofsky, Robert Strauss, Davi...> ;Hepatology. 2007 Oct 1
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Jensen, D. M., Marcellin, P., Freilich, B., Andreone, P., Di Bisceglie, A., Brandão-Mello, C. E., Reddy, K. R., Craxi, A., Martin, A. O., Teuber, G., Messinger, D., Th...> ;Ann Intern Med. 2009 Apr 21
Join now to see all